CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
  
  LEARNING OBJECTIVES

  • Appreciate the incidence, pathological and molecular characteristics and clinical relevance of HER2-low breast cancer, and understand currently available management approaches for this disease subset.
  • Recognize the current definition of HER2-low breast cancer, and be aware of the potential dynamic evolution of HER2 expression throughout the disease course.
  • Enhance interdisciplinary communication among colleagues regarding HER2 testing requirements and optimal reporting of results in order to more effectively identify patients with HER2-low breast cancer.
  • Appraise available clinical research establishing the safety and efficacy of trastuzumab deruxtecan for patients with HR-positive or HR-negative, HER2-low metastatic breast cancer, and formulate a plan to optimally incorporate this agent into treatment algorithms.
  • Recognize the spectrum, frequency and severity of treatment-emergent adverse events associated with trastuzumab deruxtecan, and develop strategies to monitor for, prevent and manage these complications.
  • Recall the design of ongoing clinical trials evaluating novel therapeutic strategies for HER2-low breast cancer, and appropriately counsel patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Video Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 1.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/SABCS2023/HER2LowBC/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Aditya Bardia, MD, MPH
  Director, Breast Cancer Research Program
  Associate Professor
  Harvard Medical School
  Attending Physician
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Consulting Agreements and Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Merck, Novartis, Pfizer Inc, Radius Health Inc, Sanofi.
  
  Lisa A Carey, MD, ScM, FASCO
  L Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research
  Deputy Director for Clinical Sciences
  Lineberger Comprehensive Cancer Center
  University of North Carolina
  Chapel Hill, North Carolina
  
  No relevant conflicts of interest to disclose.
  
  Shanu Modi, MD
  Member and Attending
  Breast Medicine Service
  Memorial Sloan Kettering Cancer Center
  Professor of Medicine
  Weill Cornell Medical College
  New York, New York
  
  Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Seagen Inc.
  
  Professor Peter Schmid, FRCP, MD, PhD
  Lead, Centre of Experimental Cancer Medicine
  Barts Cancer Institute
  London, United Kingdom
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Medivation Inc, a Pfizer Company, Novartis, OncoGenex Pharmaceuticals Inc, Roche Laboratories Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.
  
  Release date: January 2024
  Expiration date: January 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.